Primary hyperparathyroidism in young people. when should we perform genetic testing for multiple endocrine neoplasia 1 (MEN-1)?

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages 3983-3987

  Lassen, T ^a   Friis Hansen, L ^a   Rasmussen, A K ^a   Knigge, U ^a   Feldt Rasmussen, U ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CHROMOGRANIN A; PARATHYROID HORMONE; MEN1 PROTEIN, HUMAN; ONCOPROTEIN;

ADULT; BIOCHEMISTRY; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CASE REPORT; CONFERENCE PAPER; FEMALE; FOLLOW UP; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HEAD AND NECK SURGERY; HUMAN; HYPERCALCEMIA; INCIDENTAL FINDING; MEN1 GENE; MULTIPLE ENDOCRINE NEOPLASIA; NEPHROLITHIASIS; OSTEOGENESIS IMPERFECTA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PATHOGENESIS; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RECURRENT DISEASE; THYMECTOMY; TREATMENT INDICATION; ADOLESCENT; GENETICS;

ADOLESCENT; ADULT; FEMALE; GENETIC TESTING; HUMANS; HYPERPARATHYROIDISM, PRIMARY; OSTEOGENESIS IMPERFECTA; PROTO-ONCOGENE PROTEINS;

EID: 84906240184     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4491     Document Type: Conference Paper

References (29)

1. Kouvaraki MA, Lee JE, Shapiro SE, et al. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg. 2002;137(6): 641-647.
2. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9): 2990-3011.
3. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001; 86(12): 5658-5671.
4. Karges W, Schaaf L, Dralle H, Boehm BO. Clinical and molecular diagnosis of multiple endocrine neoplasia type 1. Langenbecks Arch Surg. 2002;386(8): 547-552.
5. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab. 2010;24(3): 355-370.
6. The search for the MEN1 gene. The European Consortium on MEN-1. J Intern Med. 1998;243(6): 441-446.
7. Marini F, Falchetti A, Del Monte F, et al. Multiple endocrine neoplasia type 1. Orphanet J Rare Dis. 2006;1: 38.
8. Goebel SU, Heppner C, Burns AL, et al. Genotype/phenotype correlation of multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas. J Clin Endocrinol Metab. 2000;85(1): 116-123.
9. Horiuchi K, Okamoto T, Iihara M, Tsukada T. Analysis of genotype- phenotype correlations and survival outcomes in patients with primary hyperparathyroidism caused by multiple endocrine neoplasia type 1: the experience at a single institution. Surg Today. 2013; 43(8): 894-899.
10. Piecha G, Chudek J, Wicek A. Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Int J Endocrinol. 2010;2010: 928383.
11. Eller-Vainicher C, Chiodini I, Battista C, et al. Sporadic and MEN1- related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res. 2009;24(8): 1404-1410.
12. Schaaf L, Pickel J, Zinner K, et al. Developing effective screening strategies in multiple endocrine neoplasia type 1 (MEN 1) on the basis of clinical and sequencing data of German patients with MEN 1. Exp Clin Endocrinol Diabetes. 2007;115(8): 509-517.
13. DeLellis RA, Mazzaglia P, Mangray S. Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med. 2008;132(8): 1251-1262.
14. Lourenço DM Jr, Coutinho FL, Toledo RA, Montenegro FL, Correia- Deur JE, Toledo SP. Early-onset, progressive, frequent, extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism. J Bone Miner Res. 2010;25(11): 2382-2391.
15. Lourenço DM Jr, Coutinho FL, Toledo RA, Gonçalves TD, Montenegro FL, Toledo SP. Biochemical, bone and renal patterns in hyperparathyroidism associated with multiple endocrine neoplasia type 1. Clinics (Sao Paulo). 2012;67(suppl 1): 99-108.
16. Lourenço DM Jr, Toledo RA, Mackowiak II, et al. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile. Eur J Endocrinol. 2008; 159(3): 259-274.
17. Burgess JR, David R, Greenaway TM, Parameswaran V, Shepherd JJ. Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch Surg. 1999;134(10): 1119-1123.
18. Skandarajah A, Barlier A, Morlet-Barlat N, et al. Should routine analysis of the MEN1gene be performed in all patients with primary hyperparathyroidism under 40 years of age? World J Surg. 2010; 34(6): 1294-1298.
19. Goudet P, Bonithon-Kopp C, Murat A, et al. Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'etude des Tumeurs Endocrines. Eur J Endocrinol. 2011;165(1): 97-105.
20. Goudet P, Murat A, Binquet C, et al. Risk factors and causes of death inMEN1disease. AGTE(Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34(2): 249-255.
21. Lairmore TC, Piersall LD, DeBenedetti MK, et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann Surg. 2004;239(5): 637-645; discussion 645-647.
22. Zimmermann-Belsing T, Lund AM, Christensen L, Feldt-Rasmussen U. Co-existence of osteogenesis imperfecta and hyperparathyroidism. J Endocrinol Invest. 1999;22(7): 547-550.
23. Karges W, Schaaf L, Dralle H, Boehm BO. Concepts for screening and diagnostic follow-up in multiple endocrine neoplasia type 1 (MEN1). Exp Clin Endocrinol Diabetes. 2000;108(5): 334-340.
24. Falchetti A, Marini F, Giusti F, Cavalli L, Cavalli T, Brandi ML. DNA-based test: when and why to apply it to primary hyperparathyroidism clinical phenotypes. J Intern Med. 2009;266(1): 69-83.
25. Cardinal JW, Bergman L, Hayward N, et al. A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications for mutation testing. J Med Genet. 2005;42(1): 69-74.
26. Jäger AC, Friis-Hansen L, Hansen TV, et al. Characteristics of the Danish families with multiple endocrine neoplasia type 1. Mol Cell Endocrinol. 2006;249(1-2): 123-132.
27. Langer P, Wild A, Hall A, Celik I, Rothmund M, Bartsch DK. Prevalence of multiple endocrine neoplasia type 1 in young patients with apparently sporadic primary hyperparathyroidism or pancreaticoduodenal endocrine tumours. Br J Surg. 2003;90(12): 1599-1603.
28. Roijers JF, de Wit MJ, van der Luijt RB, Ploos van Amstel HK, Höppener JW, Lips CJ. Criteria for mutation analysis inMEN1-suspected patients: MEN1 case-finding. Eur J Clin Invest. 2000;30(6): 487-492.
29. Martin D, Rosen IB, Ichise M. Evaluation of single isotope technetium 99M-sestamibi in localization efficiency for hyperparathyroidism. Am J Surg. 1996;172(6): 633-636.